SEC filing · 8-K

Foghorn Therapeutics Inc.: Restructuring or layoffs

Foghorn Therapeutics and Eli Lilly decided to stop development of FHD-909, prompting Foghorn to reduce its workforce by approximately 40%.

Filed October 1, 2026

Negative for the company

What happened

Foghorn Therapeutics and Eli Lilly decided not to advance the Phase 1 trial of FHD-909 into the expansion phase following a review of clinical data.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov Press release (EX-99.1) All documents of this filing

Back to Foghorn Therapeutics Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.